Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers · Source last updated 2020-03-16
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure
What was measured
Blood samples were collected for the analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading was done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on first study treatment dose date. Data for worst case post-Baseline is presented.
Analysis population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
Groups in this outcome
Part 1: GSK525762 2 mg QD
Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.
Part 1: GSK525762 4 mg QD
Participants were administered once daily oral dose of 4 mg GSK525762.
Part 1: GSK525762 8 mg QD
Participants were administered once daily oral dose of 8 mg GSK525762.
Part 1: GSK525762 16 mg QD
Participants were administered once daily oral dose of 16 mg GSK525762.
Part 1: GSK525762 30 mg QD
Participants were administered once daily oral dose of 30 mg GSK525762.
Part 1: GSK525762 60 mg QD
Participants were administered once daily oral dose of 60 mg GSK525762.
Part 1: GSK525762 80 mg QD
Participants were administered once daily oral dose of 80 mg GSK525762.
Part 1: GSK525762 100 mg QD
Participants were administered once daily oral dose of 100 mg GSK525762.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
3
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Reported measurements
Glucose; Any grade increase; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
3
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
7
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
24
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
8
Not reported
Not reported
Not reported
Not reported
Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
3
Not reported
Not reported
Not reported
Not reported
Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Albumin; Any grade increase; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
3
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
12
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
ALP; Any grade increase; n=2,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
7
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
ALT; Any grade increase; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
9
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
2
Not reported
Not reported
Not reported
Not reported
ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Amylase; Any grade increase; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
10
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
AST; Any grade increase; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
14
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
3
Not reported
Not reported
Not reported
Not reported
AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
30
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
30
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
30
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
15
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
8
Not reported
Not reported
Not reported
Not reported
Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
5
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
30
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
30
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
30
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Calcium; Any grade increase; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
17
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
3
Not reported
Not reported
Not reported
Not reported
Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
29
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
11
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
29
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
29
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
CK;Any grade increase;n=3,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
3
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
3
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
14
Part 1: GSK525762 100 mg QD
7
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
3
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
14
Part 1: GSK525762 100 mg QD
7
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
29
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
17
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
6
Not reported
Not reported
Not reported
Not reported
Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
29
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
29
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Troponin I;Any grade increase;n=0,0,0,0, 2,5,24,5
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
5
Part 1: GSK525762 80 mg QD
24
Part 1: GSK525762 100 mg QD
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Troponin I;Increase to Grade 3;n=0,0,0,0,2,5,24,5
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
5
Part 1: GSK525762 80 mg QD
24
Part 1: GSK525762 100 mg QD
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Troponin I;Increase to Grade 4; n=0,0,0,0,2,5,24,5
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
5
Part 1: GSK525762 80 mg QD
24
Part 1: GSK525762 100 mg QD
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
3
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
3
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
3
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Urate;Any grade increase; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Urea; Any grade increase; n=2,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
2
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
31
Part 1: GSK525762 100 mg QD
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
2
group Id
OG005
value
7
group Id
OG006
value
24
group Id
OG007
value
8
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
title
Glucose; Any grade increase; n=2,4,1,3,4,9,32,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
2
group Id
OG007
value
3
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
title
Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
title
Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
2
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
3
group Id
OG006
value
12
group Id
OG007
value
1
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
title
Albumin; Any grade increase; n=2,4,1,3,4,9,32,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
title
Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
title
Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
0
group Id
OG006
value
7
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
31
group Id
OG007
value
9
units
Participants
title
ALP; Any grade increase; n=2,4,1,3,4,9,31,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
1
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
31
group Id
OG007
value
9
units
Participants
title
ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
31
group Id
OG007
value
9
units
Participants
title
ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
1
group Id
OG006
value
9
group Id
OG007
value
2
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
title
ALT; Any grade increase; n=2,4,1,3,4,9,32,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
title
ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
title
ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9
denoms
counts
group Id
OG000
value
3
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
description
Blood samples were collected for the analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading was done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on first study treatment dose date. Data for worst case post-Baseline is presented.
groups
description
Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.
id
OG000
title
Part 1: GSK525762 2 mg QD
description
Participants were administered once daily oral dose of 4 mg GSK525762.
id
OG001
title
Part 1: GSK525762 4 mg QD
description
Participants were administered once daily oral dose of 8 mg GSK525762.
id
OG002
title
Part 1: GSK525762 8 mg QD
description
Participants were administered once daily oral dose of 16 mg GSK525762.
id
OG003
title
Part 1: GSK525762 16 mg QD
description
Participants were administered once daily oral dose of 30 mg GSK525762.
id
OG004
title
Part 1: GSK525762 30 mg QD
description
Participants were administered once daily oral dose of 60 mg GSK525762.
id
OG005
title
Part 1: GSK525762 60 mg QD
description
Participants were administered once daily oral dose of 80 mg GSK525762.
id
OG006
title
Part 1: GSK525762 80 mg QD
description
Participants were administered once daily oral dose of 100 mg GSK525762.
id
OG007
title
Part 1: GSK525762 100 mg QD
param Type
COUNT_OF_PARTICIPANTS
population Description
All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
reporting Status
POSTED
time Frame
Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure
title
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD
Triangle